Overexpression of TRPM7 is Associated with Poor Prognosis in Human Ovarian Carcinoma

Abstract

Background: The melastatin-related transient receptor potential 7 channel (TRPM7) is a nonselective cation channel that has been shown to promote tumor metastasis and progression. In this study, we determined the expression of TRPM7 in ovarian carcinomas and investigated its possible prognostic value. Materials and Methods: Samples were collected from 138 patients with ovarian cancer. Expression of TRPM7 was assessed by real-time PCR and immunohistochemistry, expressed with reference to an established scoring system and related to clinical pathological factors. Kaplan-Meier survival analysis was applied to estimate disease-free survival (DFS) and overall survival (OS). Univariate and multivariate cox regression analyses were performed to correlate TRPM7 expression levels with DFS and OS. Results: TRPM7 was highly expressed in ovarian carcinoma and significantly associated with decreased disease-free survival (DFS: median 20 months vs. 42 months, P=0.0002) and overall survival (OS: median 27 months vs. 46 months, P<0.001). Conclusion: Overexpression of TRPM7 expression is significantly associated with poor prognosis in patients with ovarian cancer.

Transient Receptor Potential Melastatin 7 as an Independent Prognostic Factor in Human Esophageal Squamous Cell Carcinoma

“…There have been other reports about the clinicopathological role of TRPM7 in several type of cancer (24)(25)(26) (26). Contrary to these reports, our results suggest that TRPM7 is negative correlated with pT and pN category and pStage in ESCC.…”

“…Rybarczyk et al demonstrated that TRPM7 was a potential biomarker of poor prognosis of pancreatic ductal adenocarcinoma (14). Wang et al showed that overexpression of TRPM7 was significantly associated with poor prognosis in patients with ovarian cancer (26). Middelbeek et al reported that TRPM7 was a strong and independent poor prognostic marker for breast cancer progression and metastasis (27).…”

Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells

“…Knock-down of TRPM7 in hepatic stellate cells prevented an increase in p-Akt and p-ERK1/2 levels following induction by PDGF-BB [34]. Additionally, silencing TRPM7 in OVCA cells or human lung fibroblast decreased the level of p-Akt, and in breast cancer cells, p-ERK1/2 was reduced [13, 35, 36]. In GBM, our lab previously showed that silencing or pharmacological inhibition of TRPM7 reduced the levels of p-Akt and p-ERK1/2, and consequently, downregulated the PI3K/Akt and MAPK/ERK pathways [4, 5].…”

“…Ion channels comprise an important target class for drug development. TRPM7 has been indicated as a potential therapeutic target for GBM [4–7] in addition to other cancer types, including: pancreatic cancer, leukemia, head and neck cancer, prostate cancer, retinoblastoma, nasopharyngeal cancer, gastric cancer, ovarian cancer, and breast cancer [8–13]. Previous studies [4–7] have suggested that the involvement of TRPM7 in GBM is due to the channel's aberrant activity and up-regulation in the cancerous tissues by using techniques to reduce TRPM7 functions (i.e.…”

DecreasedTRPM7inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway

“…TRPM7 has been reported to be ubiquitously expressed in various human tissues [16–18], suggesting that it could be implicated in important physiological processes such as cellular Mg 2+ homeostasis [18], cell viability and growth [19], anoxic neuronal cell death [20], and cell adhesion [21]. Recent studies indicated a close correlation between TRPM7 and cancer, demonstrating its involvement in retinoblastoma [22], gastric cancer [23], breast cancer [24–27], nasopharyngeal carcinoma [28], pancreatic cancer [29], prostate cancer [30], and ovarian carcinoma [31]. Our previous studies have suggested that knockdown of TRPM8 , another important subtype of the TRPM family, could inhibit proliferation of osteosarcoma and prostate cancer cells [32, 33].…”